Overview

China Pharma Intellectual Property Summit 2016 will be hold in Shanghai by YIP Events on November 17th -18th, devoted to providing a learning and networking platform for those who are engaged in pharma IP protection. We will invite renowned speakers from SIPO, USPTO, EPO, multinational pharma company, local Chinese pharma company, leading law firm to specify the newest pharma patent legislations/policies, share their IP strategies/excellent cases, and discuss hot topics. Below are some information may help to understand this summit better.

Summit Background:

IP is playing a very important role in pharmaceutical industry, especially for biopharmaceutical companies. Under the background of fierce competition, patents have undoubtedly been the most effective way to protect their products and kept the advantage of market competition. Patent protection has also become one of the core concerns, not only for multinational pharma companies, but also for local Chinese pharma companies. Biopharmaceutical industry in China is undergoing a very rapid growth, which make pharma IP protection more important and urgent.

Additionally, pharma patent topics have aroused people’s attention, including: “Patent Cliff”, patent duration under TPP, patent dispute after first biosimilars approved in US, “Patent Dance” in BPCIA, the new Patent Law in China and so on. All of these make this year’s summit more meaningful and time-efficient.

4. Building and cementing relationships with your clients/partners face to face

The participants are mainly from pharma companies, biotech companies, law firms, IP/patent agencies, IP/patent solution providers, governments, relevant associations, colleges/institutes, and the meeting scale is expected to 180-200 people. If you would like to attend or sponsor our summit, please feel free to call / email us to reserve your seats ASAP!

Thanks again for your attention and looking forward to your participation!
Sincerely,

The Status Quo and Challenges of Pharmaceutical Patent in ChinaWu Li, Senior Consultant, AnJie Law Firm

1700

Issues to Be Considered When Launching a Generic Drug in Europe ● The issue of finding and evaluating relevant third party rights which may cause problems, and steps that can be taken to challenge these rights
● The issue of supplementary protection certificates (SPCs) and understand how third-party SPC rights may be challenged
● Overview of the Unitary Patent Court and how the recent Brexit vote is likely to affect the implementation of this new system and also how the UK's decision to leave Europe court might affect patentees.Jonathan D.M. Atkinson, Partner, HGF Limited

What’s the IP Risk and Strategy When Local Chinese Pharmaceutical Company "Going-Out"? ● Why local China pharma companies need “going-out”?
● Challenges and risks of global IP protection
● The importance of communication with lawyers in the target market countries
● The best time of IP protectionsYunli Xue, SVP, Luye Pharma Group Ltd

1440

Risk and Reward of IP for Pharma Companies in China

● The importance of IP to pharmaceutical industry

● The rapid development of China IP environment in recent years

● The restrictive IP factors in development of pharmaceutical industry

● The opportunity and challenge of multinational pharmaceutical company IP management

Kent Yang, Senior Patent Attorney, Novartis

1520

Coffee Break & Refreshments

1550

The Origins and Operation of the Hatch-Waxman Act and Its Likely Impact in China

Randall Rader, Former Chief Judge, the United States Court of Appeals for the Federal Circuit (Retired in 2014)